Pharma PLI to increase exports
Indian government is expecting pharmaceutical industry to fetch incremental sales worth Rs. 294,000 crore and exports up to Rs. 196,000 crore by FY 2027-28
Indian government is expecting pharmaceutical industry to fetch incremental sales worth Rs. 294,000 crore and exports up to Rs. 196,000 crore by FY 2027-28
The company is pursuing specific goals in the areas of science and technology, value chain as well as climate and the environment.
Production of Sputnik V at Panacea Biotec sites will help facilitate global supply of Sputnik V to international partners of RDIF
TCPCL is the largest and only commercial manufacturer of SDAs for zeolites in India
Besides powering the drug discovery efforts, phytopharmaceuticals have a huge potential to create a niche market for itself, thereby helping to expand the bio-economy.
The consideration to be paid will be AUD 2.0 mn for 12.5% stake.
The next phase of growth in pharma depends on the industry-oriented workforce, risk investment, academic revamp, and creation of R&D hubs, say experts .
Pharma industry is ready to embrace technology platforms with a keen focus on automation in manufacturing and digital health investment.
A mix of favorable government policies and a positive environment will create a win-win situation for all stakeholders
The company expects to generate an EBITDA margin before special items of around 27 percent in 2021.
Subscribe To Our Newsletter & Stay Updated